董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susannah Gray | 女 | Director | 66 | 28.75万美元 | 16.99 | 2026-05-26 |
| Luke Marker | 男 | Director | 41 | 25.25万美元 | 13.81 | 2026-05-26 |
| Sean Cunningham | 男 | Director | 51 | 26.00万美元 | 13.81 | 2026-05-26 |
| Constantine Mihas | 男 | Director | 59 | 26.25万美元 | 13.81 | 2026-05-26 |
| John DeFord | 男 | Director | 64 | 28.50万美元 | 14.86 | 2026-05-26 |
| Bernd Brust | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-05-26 |
| John DeFord | 男 | Director | 64 | 未披露 | 未持股 | 2026-05-26 |
| Bernd Brust | 男 | Chief Executive Officer and Director | 58 | 1012.97万美元 | 未持股 | 2026-05-26 |
| R. Andrew Eckert | 男 | Chairman of the Board and Director | 65 | 67.50万美元 | 25.02 | 2026-05-26 |
| Gregory T. Lucier | 男 | Director | 61 | 25.25万美元 | 26.49 | 2026-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christine Dolan | 女 | Executive Vice President | 58 | 145.42万美元 | 43.45 | 2026-05-26 |
| Kurt Oreshack | 男 | Executive Vice President and General Counsel and Secretary | 46 | 147.10万美元 | 31.98 | 2026-05-26 |
| Bernd Brust | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-05-26 |
| Raj Asarpota | 男 | Chief Financial Officer | 59 | 350.68万美元 | 未持股 | 2026-05-26 |
| Bernd Brust | 男 | Chief Executive Officer and Director | 58 | 1012.97万美元 | 未持股 | 2026-05-26 |
董事简历
中英对照 | 中文 | 英文- Susannah Gray
-
Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University. - Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
- Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University.
- Luke Marker
-
Luke Marker自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直在董事会任职，并自2016年起担任MLSH 1的董事会成员。Marker先生于2009年加入GTCR，目前担任董事总经理。在加入GTCR之前，他曾在雷曼兄弟和巴克莱银行资本的投资银行部门工作。Marker先生拥有哈佛商学院的MBA学位和卡拉马祖学院的数学和经济学学士学位。Marker先生还担任私营公司BioCoat、Corza Medical和Regatta Medical的董事。
Luke Marker has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served as a member of MLSH 1's board since 2016. Mr. Marker joined GTCR in 2009 where he is currently Managing Director. Prior to joining GTCR, he worked in the investment banking division at Lehman Brothers and Barclays Capital. Mr. Marker holds an MBA with distinction from Harvard Business School and a BA in Mathematics and Economics from Kalamazoo College. Mr. Marker also serves as a director of private companies Biocoat, Corza Medical and Regatta Medical. - Luke Marker自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直在董事会任职，并自2016年起担任MLSH 1的董事会成员。Marker先生于2009年加入GTCR，目前担任董事总经理。在加入GTCR之前，他曾在雷曼兄弟和巴克莱银行资本的投资银行部门工作。Marker先生拥有哈佛商学院的MBA学位和卡拉马祖学院的数学和经济学学士学位。Marker先生还担任私营公司BioCoat、Corza Medical和Regatta Medical的董事。
- Luke Marker has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served as a member of MLSH 1's board since 2016. Mr. Marker joined GTCR in 2009 where he is currently Managing Director. Prior to joining GTCR, he worked in the investment banking division at Lehman Brothers and Barclays Capital. Mr. Marker holds an MBA with distinction from Harvard Business School and a BA in Mathematics and Economics from Kalamazoo College. Mr. Marker also serves as a director of private companies Biocoat, Corza Medical and Regatta Medical.
- Sean Cunningham
-
Sean Cunningham自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直担任董事会成员，自2022年10月起担任Maravai Lifesciences Holdings, Inc.提名、治理和风险委员会成员，并自2016年3月起担任MLSH 1的董事会成员。Cunningham先生还担任医疗保健公司Sotera Health Company（“Sotera健康”）的董事会成员。坎宁安先生于2001年加入GTCR，目前担任董事总经理和医疗保健集团负责人。坎宁安此前是波士顿咨询公司的一名顾问。坎宁安先生拥有宾夕法尼亚大学沃顿商学院MBA学位以及达特茅斯学院工程科学学士和学士学位。
Sean Cunningham has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and on Maravai Lifesciences Holdings, Inc.'s Nominating, Governance and Risk Committee since October 2022, and has served as a member of MLSH 1's board since March 2016. Mr. Cunningham also serves on the Board of Directors of Sotera Health Company ("Sotera Health"), a healthcare company. Mr. Cunningham joined GTCR in 2001 where he is currently a Managing Director and Head of the Healthcare Group. Mr. Cunningham was previously a consultant with The Boston Consulting Group. Mr. Cunningham holds an MBA from the Wharton School at the University of Pennsylvania as well as a BA and BE in Engineering Sciences from Dartmouth College. - Sean Cunningham自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直担任董事会成员，自2022年10月起担任Maravai Lifesciences Holdings, Inc.提名、治理和风险委员会成员，并自2016年3月起担任MLSH 1的董事会成员。Cunningham先生还担任医疗保健公司Sotera Health Company（“Sotera健康”）的董事会成员。坎宁安先生于2001年加入GTCR，目前担任董事总经理和医疗保健集团负责人。坎宁安此前是波士顿咨询公司的一名顾问。坎宁安先生拥有宾夕法尼亚大学沃顿商学院MBA学位以及达特茅斯学院工程科学学士和学士学位。
- Sean Cunningham has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and on Maravai Lifesciences Holdings, Inc.'s Nominating, Governance and Risk Committee since October 2022, and has served as a member of MLSH 1's board since March 2016. Mr. Cunningham also serves on the Board of Directors of Sotera Health Company ("Sotera Health"), a healthcare company. Mr. Cunningham joined GTCR in 2001 where he is currently a Managing Director and Head of the Healthcare Group. Mr. Cunningham was previously a consultant with The Boston Consulting Group. Mr. Cunningham holds an MBA from the Wharton School at the University of Pennsylvania as well as a BA and BE in Engineering Sciences from Dartmouth College.
- Constantine Mihas
-
Constantine Mihas自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直担任董事会成员，自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员，并自2016年3月起担任MLSH 1的董事会成员。此前，Mihas先生曾在Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票时担任薪酬和提名委员会主席，直至2022年10月。Mihas先生还担任Sotera健康的董事会成员。Mihas先生于2001年加入GTCR，目前担任联席首席执行官和董事总经理。在加入GTCR之前，Mihas先生是专业食品零售商Delray Farms，LLC（“Delray Farms”）的首席执行官和联合创始人。在加入Delray Farms之前，米哈斯曾任职于咨询公司麦肯锡公司。米哈斯先生拥有哈佛商学院的MBA学位和芝加哥伊利诺伊大学的金融和经济学学士学位。
Constantine Mihas has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022, and has served as a member MLSH 1's board since March 2016. Previously, Mr. Mihas served as Chair of the Compensation and Nominating Committee from Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 until October 2022. Mr. Mihas also serves on the Board of Directors of Sotera Health. Mr. Mihas joined GTCR in 2001 where he is currently Co CEO and Managing Director. Prior to joining GTCR, Mr. Mihas was Chief Executive Officer and co founder of Delray Farms, LLC ("Delray Farms"), a specialty food retailer. Prior to Delray Farms, Mr. Mihas was with McKinsey & Company, Inc., a consulting firm. Mr. Mihas holds an MBA with distinction from the Harvard Business School and a BS in Finance and Economics from the University of Illinois, Chicago. - Constantine Mihas自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来一直担任董事会成员，自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员，并自2016年3月起担任MLSH 1的董事会成员。此前，Mihas先生曾在Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票时担任薪酬和提名委员会主席，直至2022年10月。Mihas先生还担任Sotera健康的董事会成员。Mihas先生于2001年加入GTCR，目前担任联席首席执行官和董事总经理。在加入GTCR之前，Mihas先生是专业食品零售商Delray Farms，LLC（“Delray Farms”）的首席执行官和联合创始人。在加入Delray Farms之前，米哈斯曾任职于咨询公司麦肯锡公司。米哈斯先生拥有哈佛商学院的MBA学位和芝加哥伊利诺伊大学的金融和经济学学士学位。
- Constantine Mihas has served on the Board since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022, and has served as a member MLSH 1's board since March 2016. Previously, Mr. Mihas served as Chair of the Compensation and Nominating Committee from Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 until October 2022. Mr. Mihas also serves on the Board of Directors of Sotera Health. Mr. Mihas joined GTCR in 2001 where he is currently Co CEO and Managing Director. Prior to joining GTCR, Mr. Mihas was Chief Executive Officer and co founder of Delray Farms, LLC ("Delray Farms"), a specialty food retailer. Prior to Delray Farms, Mr. Mihas was with McKinsey & Company, Inc., a consulting firm. Mr. Mihas holds an MBA with distinction from the Harvard Business School and a BS in Finance and Economics from the University of Illinois, Chicago.
- John DeFord
-
John DeFord于2021年从Becton、Dickinson和NYSE：BDX公司退休，Becton、Dickinson是一家全球领先的医疗技术公司，生产和销售医疗设备、仪器系统和试剂。自2017年BDX收购C.R.Bard，Inc.以来，他一直担任执行副总裁兼首席技术官，直至2021。此前，DeFord博士是C.R.Bard，股份有限公司的科学、技术和临床事务高级副总裁。在收购时，C.R。Bard，股份有限公司是创新、血管、泌尿、肿瘤和外科专业产品领域的生命增强医疗技术。他之前的工作经验包括担任风险投资基金Early Stage Partners的常务董事，以及私人医疗器械制造商库克集团（Cook Group Incorporated）的总裁兼首席执行官。DeFord博士是NuVasive，Inc.（纳斯达克代码：NUVA）的董事，一家医疗器械公司，专注于微创手术和世界级外科医生教育的医疗器械和程序，他是提名、公司治理和合规委员会的成员。
John DeFord is currently chairman, chief executive officer and president of Samothrace Medical Innovations, Inc., a privately held medical technology company, which he co founded in March 2022. Previoly, Dr. DeFord served as executive vice president and chief technology officer of Becton, Dickinson and Company (NYSE: BDX) (medical technology and manufacturing) from 2017 until 2021. Prior to that, he was senior vice president of Science, Technology and Clinical Affairs for C.R. Bard, Inc. (medical technology manufacturing), which was acquired by BDX in 2017, managing director of Early Stage Partners, a venture capital fund, and president and chief executive officer of Cook Incorporated, a privately held medical device manufacturer. - John DeFord于2021年从Becton、Dickinson和NYSE：BDX公司退休，Becton、Dickinson是一家全球领先的医疗技术公司，生产和销售医疗设备、仪器系统和试剂。自2017年BDX收购C.R.Bard，Inc.以来，他一直担任执行副总裁兼首席技术官，直至2021。此前，DeFord博士是C.R.Bard，股份有限公司的科学、技术和临床事务高级副总裁。在收购时，C.R。Bard，股份有限公司是创新、血管、泌尿、肿瘤和外科专业产品领域的生命增强医疗技术。他之前的工作经验包括担任风险投资基金Early Stage Partners的常务董事，以及私人医疗器械制造商库克集团（Cook Group Incorporated）的总裁兼首席执行官。DeFord博士是NuVasive，Inc.（纳斯达克代码：NUVA）的董事，一家医疗器械公司，专注于微创手术和世界级外科医生教育的医疗器械和程序，他是提名、公司治理和合规委员会的成员。
- John DeFord is currently chairman, chief executive officer and president of Samothrace Medical Innovations, Inc., a privately held medical technology company, which he co founded in March 2022. Previoly, Dr. DeFord served as executive vice president and chief technology officer of Becton, Dickinson and Company (NYSE: BDX) (medical technology and manufacturing) from 2017 until 2021. Prior to that, he was senior vice president of Science, Technology and Clinical Affairs for C.R. Bard, Inc. (medical technology manufacturing), which was acquired by BDX in 2017, managing director of Early Stage Partners, a venture capital fund, and president and chief executive officer of Cook Incorporated, a privately held medical device manufacturer.
- Bernd Brust
-
Bernd Brust自2025年6月起担任董事会成员并担任Maravai Lifesciences Holdings, Inc.的首席执行官。在加入Maravai之前，Brust先生曾于2021年至2025年担任执行主席，并于2014年至2021年担任生命科学公司Antylia Scientific（f/k/a Cole Parmer Instrument Company）的首席执行官。Brust先生此前曾于2011年至2013年担任医药封装公司Qualicaps，Inc.的首席执行官。在此之前，Brust先生曾在Life Technologies，Inc.（“Life Technologies”）担任高级领导职务，并在Invitrogen Corporation（Life Technologies的前身）和GE Medical Systems担任高管职务。Brust先生拥有Middelbare Technische学校的工程学学位。
Bernd Brust has served on the Board and as Maravai Lifesciences Holdings, Inc.'s Chief Executive Officer since June 2025. Prior to joining Maravai, Mr. Brust served as Executive Chairman, from 2021 to 2025, and as Chief Executive Officer, from 2014 to 2021, of Antylia Scientific (f/k/a Cole Parmer Instrument Company), a life sciences company. Mr. Brust previously served as Chief Executive Officer of Qualicaps, Inc., a pharmaceutical encapsulation company, from 2011 to 2013. Before that, Mr. Brust held senior leadership roles at Life Technologies, Inc. ("Life Technologies") as well as executive positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems. Mr. Brust holds a degree in engineering from the Middelbare Technische School. - Bernd Brust自2025年6月起担任董事会成员并担任Maravai Lifesciences Holdings, Inc.的首席执行官。在加入Maravai之前，Brust先生曾于2021年至2025年担任执行主席，并于2014年至2021年担任生命科学公司Antylia Scientific（f/k/a Cole Parmer Instrument Company）的首席执行官。Brust先生此前曾于2011年至2013年担任医药封装公司Qualicaps，Inc.的首席执行官。在此之前，Brust先生曾在Life Technologies，Inc.（“Life Technologies”）担任高级领导职务，并在Invitrogen Corporation（Life Technologies的前身）和GE Medical Systems担任高管职务。Brust先生拥有Middelbare Technische学校的工程学学位。
- Bernd Brust has served on the Board and as Maravai Lifesciences Holdings, Inc.'s Chief Executive Officer since June 2025. Prior to joining Maravai, Mr. Brust served as Executive Chairman, from 2021 to 2025, and as Chief Executive Officer, from 2014 to 2021, of Antylia Scientific (f/k/a Cole Parmer Instrument Company), a life sciences company. Mr. Brust previously served as Chief Executive Officer of Qualicaps, Inc., a pharmaceutical encapsulation company, from 2011 to 2013. Before that, Mr. Brust held senior leadership roles at Life Technologies, Inc. ("Life Technologies") as well as executive positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems. Mr. Brust holds a degree in engineering from the Middelbare Technische School.
- John DeFord
-
John DeFord自2023年7月起担任董事会成员，自2023年9月起担任Maravai Lifesciences Holdings, Inc.审计委员会以及薪酬和领导力发展委员会成员。他于2024年6月担任Maravai Lifesciences Holdings, Inc.薪酬和领导力发展委员会主席。DeFord博士还担任精密技术公司Nordson Corporation的董事会成员，并已被提议任命为皇家飞利浦公司的监事会成员。DeFord博士于2023年9月至2026年3月期间担任医疗器械公司Globus医疗公司的董事。自2022年3月退休后，DeFord博士一直担任医疗技术公司Samothrace Medical Innovations，Inc.的董事长、首席执行官兼总裁。DeFord博士在医疗保健和医疗设备行业拥有超过35年的经验。DeFord博士于2018年6月起担任全球医疗技术公司碧迪医疗公司（“Becton Dickinson”）的执行副总裁兼首席技术官，直至2021年5月从Becton Dickinson退休。DeFord博士于2017年12月加入Becton Dickinson，负责收购医疗技术公司C.R. Bard，Inc.（“Bard”），在那里他担任Becton Dickinson收购后介入部门的研发高级副总裁。在收购之前，DeFord博士自2004年1月起在Bard担任多种科学和技术职务，在Becton Dickinson收购时担任科学、技术和临床事务高级副总裁。在加入Bard之前，DeFord博士是风险投资基金Early Stage Partners的董事总经理。在加入Early Stage Partners之前，DeFord博士是医疗设备制造商Cook Incorporated的总裁兼首席执行官。DeFord博士拥有普渡大学电气/生物医学工程博士学位、电气工程硕士学位和电气工程学士学位。
John DeFord has served on the Board since July 2023 and on Maravai Lifesciences Holdings, Inc.'s Audit Committee and Compensation and Leadership Development Committee since September 2023. He assumed the role of Chair of Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee in June 2024. Dr. DeFord also serves on the Board of Directors of Nordson Corporation, a precision technology company, and has been proposed to be appointed to Royal Philips Company's supervisory board. Dr. DeFord served as a director of Globus Medical Inc., a medical device company, from September 2023 to March 2026. Dr. DeFord has been the Chairman, Chief Executive Officer and President of Samothrace Medical Innovations, Inc., a medical technology company, since coming out of retirement in March 2022. Dr. DeFord has over 35 years of experience in the healthcare and medical device industries. Dr. DeFord served as Executive Vice President and Chief Technology Officer of Becton, Dickinson and Company ("Becton Dickinson"), a global medical technology company, from June 2018 until he retired from Becton Dickinson in May 2021. Dr. DeFord joined Becton Dickinson in December 2017 in connection with its acquisition of C.R. Bard, Inc. ("Bard"), a medical technology company, where he served as the Senior Vice President of Research and Development for Becton Dickinson's interventional segment post acquisition. Prior to the acquisition, Dr. DeFord served in a variety of science and technology roles at Bard since January 2004 and was Senior Vice President of Science, Technology and Clinical Affairs at the time of the acquisition by Becton Dickinson. Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was President and Chief Executive Officer of Cook Incorporated, medical device manufacturer. Dr. DeFord holds a PhD in Electrical/Biomedical Engineering, a MS in Electrical Engineering and a BS in Electrical Engineering from Purdue University. - John DeFord自2023年7月起担任董事会成员，自2023年9月起担任Maravai Lifesciences Holdings, Inc.审计委员会以及薪酬和领导力发展委员会成员。他于2024年6月担任Maravai Lifesciences Holdings, Inc.薪酬和领导力发展委员会主席。DeFord博士还担任精密技术公司Nordson Corporation的董事会成员，并已被提议任命为皇家飞利浦公司的监事会成员。DeFord博士于2023年9月至2026年3月期间担任医疗器械公司Globus医疗公司的董事。自2022年3月退休后，DeFord博士一直担任医疗技术公司Samothrace Medical Innovations，Inc.的董事长、首席执行官兼总裁。DeFord博士在医疗保健和医疗设备行业拥有超过35年的经验。DeFord博士于2018年6月起担任全球医疗技术公司碧迪医疗公司（“Becton Dickinson”）的执行副总裁兼首席技术官，直至2021年5月从Becton Dickinson退休。DeFord博士于2017年12月加入Becton Dickinson，负责收购医疗技术公司C.R. Bard，Inc.（“Bard”），在那里他担任Becton Dickinson收购后介入部门的研发高级副总裁。在收购之前，DeFord博士自2004年1月起在Bard担任多种科学和技术职务，在Becton Dickinson收购时担任科学、技术和临床事务高级副总裁。在加入Bard之前，DeFord博士是风险投资基金Early Stage Partners的董事总经理。在加入Early Stage Partners之前，DeFord博士是医疗设备制造商Cook Incorporated的总裁兼首席执行官。DeFord博士拥有普渡大学电气/生物医学工程博士学位、电气工程硕士学位和电气工程学士学位。
- John DeFord has served on the Board since July 2023 and on Maravai Lifesciences Holdings, Inc.'s Audit Committee and Compensation and Leadership Development Committee since September 2023. He assumed the role of Chair of Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee in June 2024. Dr. DeFord also serves on the Board of Directors of Nordson Corporation, a precision technology company, and has been proposed to be appointed to Royal Philips Company's supervisory board. Dr. DeFord served as a director of Globus Medical Inc., a medical device company, from September 2023 to March 2026. Dr. DeFord has been the Chairman, Chief Executive Officer and President of Samothrace Medical Innovations, Inc., a medical technology company, since coming out of retirement in March 2022. Dr. DeFord has over 35 years of experience in the healthcare and medical device industries. Dr. DeFord served as Executive Vice President and Chief Technology Officer of Becton, Dickinson and Company ("Becton Dickinson"), a global medical technology company, from June 2018 until he retired from Becton Dickinson in May 2021. Dr. DeFord joined Becton Dickinson in December 2017 in connection with its acquisition of C.R. Bard, Inc. ("Bard"), a medical technology company, where he served as the Senior Vice President of Research and Development for Becton Dickinson's interventional segment post acquisition. Prior to the acquisition, Dr. DeFord served in a variety of science and technology roles at Bard since January 2004 and was Senior Vice President of Science, Technology and Clinical Affairs at the time of the acquisition by Becton Dickinson. Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was President and Chief Executive Officer of Cook Incorporated, medical device manufacturer. Dr. DeFord holds a PhD in Electrical/Biomedical Engineering, a MS in Electrical Engineering and a BS in Electrical Engineering from Purdue University.
- Bernd Brust
-
Bernd Brust，他曾于2010年担任Life Technologies公司的商业运营总裁，以及Life Technologies公司的分子医学总裁。从2006年11月到2008年11月，他曾担任Invitrogen Corporation（于2008年11月与Applied Biosystems公司合并成Life Technologies公司）的负责全球销售的高级副总裁。他于2004年加入Invitrogen Corporation，也曾担任总经理兼欧洲运营副总裁（直到2006年11月）。加入Invitrogen Corporation之前，他曾担任GE Medical Systems Information Technologies公司的多种高级领导职务，包括负责销售和营销的总经理。他持有MTS（位于阿姆斯特丹）的工程学位。他是the San Diego Regional Chamber of Commerce、BIOCOM（世界上最大的地区生命科学协会）的董事会成员，并代表南加州的550多家公司。
Bernd Brust served as President of Commercial Operations of Life Technologies in 2010and is now the President of Molecular Medicine of Life Technologies. From November 2006 to November 2008Mr. Brust served as Senior Vice President of Global Sales of Invitrogen Corporation,which merged with Applied Biosystems in November 2008 to form Life Technologies. Mr. Brust joined Invitrogen Corporation in 2004 and served as General Manager and Vice President of European Operations until November 2006. Prior to joining Invitrogen Corporation,he served in various senior leadership roles at GE Medical Systems Information Technologies,including as General Manager of Sales & Marketing. Mr. Brust holds a degree in Engineering from MTS in Amsterdam. Mr. Brust is a board member of the San Diego Regional Chamber of Commerce and BIOCOM,the largest regional life science association in the world,representing more than 550 member companies in Southern California. - Bernd Brust，他曾于2010年担任Life Technologies公司的商业运营总裁，以及Life Technologies公司的分子医学总裁。从2006年11月到2008年11月，他曾担任Invitrogen Corporation（于2008年11月与Applied Biosystems公司合并成Life Technologies公司）的负责全球销售的高级副总裁。他于2004年加入Invitrogen Corporation，也曾担任总经理兼欧洲运营副总裁（直到2006年11月）。加入Invitrogen Corporation之前，他曾担任GE Medical Systems Information Technologies公司的多种高级领导职务，包括负责销售和营销的总经理。他持有MTS（位于阿姆斯特丹）的工程学位。他是the San Diego Regional Chamber of Commerce、BIOCOM（世界上最大的地区生命科学协会）的董事会成员，并代表南加州的550多家公司。
- Bernd Brust served as President of Commercial Operations of Life Technologies in 2010and is now the President of Molecular Medicine of Life Technologies. From November 2006 to November 2008Mr. Brust served as Senior Vice President of Global Sales of Invitrogen Corporation,which merged with Applied Biosystems in November 2008 to form Life Technologies. Mr. Brust joined Invitrogen Corporation in 2004 and served as General Manager and Vice President of European Operations until November 2006. Prior to joining Invitrogen Corporation,he served in various senior leadership roles at GE Medical Systems Information Technologies,including as General Manager of Sales & Marketing. Mr. Brust holds a degree in Engineering from MTS in Amsterdam. Mr. Brust is a board member of the San Diego Regional Chamber of Commerce and BIOCOM,the largest regional life science association in the world,representing more than 550 member companies in Southern California.
- R. Andrew Eckert
-
R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company. - R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
- R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company.
- Gregory T. Lucier
-
Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
Gregory T. Lucier has served as Non Executive Chairman of the Dentsply Sirona Board of Directors since January 1, 2024. Mr. Lucier has served as the Chief Executive Officer of Corza Health, a life sciences company, since 2018 and is an over 35 year veteran of the healthcare industry. Prior to Corza Health, Mr. Lucier was Chairman and Chief Executive Officer of NuVasive, a global technology leader in minimally invasive spine and orthopedic surgery, from 2015 to 2018. Prior to NuVasive, from 2003 to 2014, Mr. Lucier served as Chairman and CEO of Life Technologies. Mr. Lucier's early career included roles as a corporate officer of General Electric Company and as an executive at GE Medical Systems Information Technologies. He is a member of the Boards of Directors of Maravai LifeSciences Holdings, Inc. and Avantor, Inc., where he serves on both its Compensation & Human Resources Committee and its Nominating and Governance Committee. Mr. Lucier holds a Bachelor's in Industrial Engineering from Pennsylvania State University and a Master's in Business Administration from Harvard Business School. - Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
- Gregory T. Lucier has served as Non Executive Chairman of the Dentsply Sirona Board of Directors since January 1, 2024. Mr. Lucier has served as the Chief Executive Officer of Corza Health, a life sciences company, since 2018 and is an over 35 year veteran of the healthcare industry. Prior to Corza Health, Mr. Lucier was Chairman and Chief Executive Officer of NuVasive, a global technology leader in minimally invasive spine and orthopedic surgery, from 2015 to 2018. Prior to NuVasive, from 2003 to 2014, Mr. Lucier served as Chairman and CEO of Life Technologies. Mr. Lucier's early career included roles as a corporate officer of General Electric Company and as an executive at GE Medical Systems Information Technologies. He is a member of the Boards of Directors of Maravai LifeSciences Holdings, Inc. and Avantor, Inc., where he serves on both its Compensation & Human Resources Committee and its Nominating and Governance Committee. Mr. Lucier holds a Bachelor's in Industrial Engineering from Pennsylvania State University and a Master's in Business Administration from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Christine Dolan
Christine Dolan，她曾担任Maravai Lifesciences Holdings, Inc.的首席运营官。自2017年10月起担任生物制品安全检测业务部门。加入Maravai之前，Dolan女士是Catalent, Inc.的产品开发高级副总裁。“Catalent”是一家生物技术公司，Dolan女士在那里工作了8年多。加入Catalent之前，Dolan女士曾担任GE Healthcare（医疗技术公司）的核运营和全球质量控制总监以及QC、验证和供应链管理总监3年多。加入GE Healthcare之前，Dolan女士在Amersham担任QC和材料管理总监，在那里她工作了十多年。Dolan女士持有Lenoir-Rhyne College的生物学学士学位。
Christine Dolan has served as Executive Vice President and General Manager, Cygnus Technologies since January 1, 2024. Prior to her current role, Ms. Dolan served as the Chief Operating Officer of Maravai Lifesciences Holdings, Inc.'s Biologics Safety Testing operating division from October 2017 to December 2023. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles, including at Catalent Pharma Solutions, a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products, from September 2009 to October 2017, where she served in progressively more senior roles including Senior Vice President of Product Development, VP of Global Operations and VP GM of Development and Analytical Services. Prior to joining Catalent Pharma Solutions, from 1995 to 2009, Ms. Dolan was Director of Nuclear Operations and Global Quality Control at GE Healthcare, a global medical technology company, and Amersham Health, a leader in medical diagnostics and life sciences. where she worked in progressive management roles. Ms. Dolan holds a BS in Biology from Lenoir Rhyne College.- Christine Dolan，她曾担任Maravai Lifesciences Holdings, Inc.的首席运营官。自2017年10月起担任生物制品安全检测业务部门。加入Maravai之前，Dolan女士是Catalent, Inc.的产品开发高级副总裁。“Catalent”是一家生物技术公司，Dolan女士在那里工作了8年多。加入Catalent之前，Dolan女士曾担任GE Healthcare（医疗技术公司）的核运营和全球质量控制总监以及QC、验证和供应链管理总监3年多。加入GE Healthcare之前，Dolan女士在Amersham担任QC和材料管理总监，在那里她工作了十多年。Dolan女士持有Lenoir-Rhyne College的生物学学士学位。
- Christine Dolan has served as Executive Vice President and General Manager, Cygnus Technologies since January 1, 2024. Prior to her current role, Ms. Dolan served as the Chief Operating Officer of Maravai Lifesciences Holdings, Inc.'s Biologics Safety Testing operating division from October 2017 to December 2023. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles, including at Catalent Pharma Solutions, a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products, from September 2009 to October 2017, where she served in progressively more senior roles including Senior Vice President of Product Development, VP of Global Operations and VP GM of Development and Analytical Services. Prior to joining Catalent Pharma Solutions, from 1995 to 2009, Ms. Dolan was Director of Nuclear Operations and Global Quality Control at GE Healthcare, a global medical technology company, and Amersham Health, a leader in medical diagnostics and life sciences. where she worked in progressive management roles. Ms. Dolan holds a BS in Biology from Lenoir Rhyne College.
- Kurt Oreshack
Kurt Oreshack自2020年11月起担任Maravai Lifesciences Holdings, Inc.执行副总裁、总法律顾问和秘书。在加入Maravai之前，Oreshack先生在国际律师事务所Gunderson Dettmer从事公司法和证券法业务，并且是Human Longevity，Inc.的总法律顾问，该公司是一家位于圣地亚哥的基因组研究和体外诊断公司。Oreshack先生获得了圣母大学法学院的京东学位和芝加哥洛约拉大学的学士学位。他是加利福尼亚州律师协会的成员。
Kurt Oreshack has served as Maravai Lifesciences Holdings, Inc.'s Executive Vice President, General Counsel and Secretary since November 2020. Prior to joining Maravai, Mr. Oreshack practiced corporate and securities law at Gunderson Dettmer, an international law firm, and was General Counsel of Human Longevity, Inc., a San Diego based genomic research and in vitro diagnostics company. Mr. Oreshack received a JD from the University of Notre Dame Law School and a BA from Loyola University Chicago. He is a member of the State Bar of California.- Kurt Oreshack自2020年11月起担任Maravai Lifesciences Holdings, Inc.执行副总裁、总法律顾问和秘书。在加入Maravai之前，Oreshack先生在国际律师事务所Gunderson Dettmer从事公司法和证券法业务，并且是Human Longevity，Inc.的总法律顾问，该公司是一家位于圣地亚哥的基因组研究和体外诊断公司。Oreshack先生获得了圣母大学法学院的京东学位和芝加哥洛约拉大学的学士学位。他是加利福尼亚州律师协会的成员。
- Kurt Oreshack has served as Maravai Lifesciences Holdings, Inc.'s Executive Vice President, General Counsel and Secretary since November 2020. Prior to joining Maravai, Mr. Oreshack practiced corporate and securities law at Gunderson Dettmer, an international law firm, and was General Counsel of Human Longevity, Inc., a San Diego based genomic research and in vitro diagnostics company. Mr. Oreshack received a JD from the University of Notre Dame Law School and a BA from Loyola University Chicago. He is a member of the State Bar of California.
- Bernd Brust
Bernd Brust自2025年6月起担任董事会成员并担任Maravai Lifesciences Holdings, Inc.的首席执行官。在加入Maravai之前，Brust先生曾于2021年至2025年担任执行主席，并于2014年至2021年担任生命科学公司Antylia Scientific（f/k/a Cole Parmer Instrument Company）的首席执行官。Brust先生此前曾于2011年至2013年担任医药封装公司Qualicaps，Inc.的首席执行官。在此之前，Brust先生曾在Life Technologies，Inc.（“Life Technologies”）担任高级领导职务，并在Invitrogen Corporation（Life Technologies的前身）和GE Medical Systems担任高管职务。Brust先生拥有Middelbare Technische学校的工程学学位。
Bernd Brust has served on the Board and as Maravai Lifesciences Holdings, Inc.'s Chief Executive Officer since June 2025. Prior to joining Maravai, Mr. Brust served as Executive Chairman, from 2021 to 2025, and as Chief Executive Officer, from 2014 to 2021, of Antylia Scientific (f/k/a Cole Parmer Instrument Company), a life sciences company. Mr. Brust previously served as Chief Executive Officer of Qualicaps, Inc., a pharmaceutical encapsulation company, from 2011 to 2013. Before that, Mr. Brust held senior leadership roles at Life Technologies, Inc. ("Life Technologies") as well as executive positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems. Mr. Brust holds a degree in engineering from the Middelbare Technische School.- Bernd Brust自2025年6月起担任董事会成员并担任Maravai Lifesciences Holdings, Inc.的首席执行官。在加入Maravai之前，Brust先生曾于2021年至2025年担任执行主席，并于2014年至2021年担任生命科学公司Antylia Scientific（f/k/a Cole Parmer Instrument Company）的首席执行官。Brust先生此前曾于2011年至2013年担任医药封装公司Qualicaps，Inc.的首席执行官。在此之前，Brust先生曾在Life Technologies，Inc.（“Life Technologies”）担任高级领导职务，并在Invitrogen Corporation（Life Technologies的前身）和GE Medical Systems担任高管职务。Brust先生拥有Middelbare Technische学校的工程学学位。
- Bernd Brust has served on the Board and as Maravai Lifesciences Holdings, Inc.'s Chief Executive Officer since June 2025. Prior to joining Maravai, Mr. Brust served as Executive Chairman, from 2021 to 2025, and as Chief Executive Officer, from 2014 to 2021, of Antylia Scientific (f/k/a Cole Parmer Instrument Company), a life sciences company. Mr. Brust previously served as Chief Executive Officer of Qualicaps, Inc., a pharmaceutical encapsulation company, from 2011 to 2013. Before that, Mr. Brust held senior leadership roles at Life Technologies, Inc. ("Life Technologies") as well as executive positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems. Mr. Brust holds a degree in engineering from the Middelbare Technische School.
- Raj Asarpota
Raj Asarpota自2025年6月起担任Maravai Lifesciences Holdings, Inc.的首席财务官。在加入Maravai之前，他于2021年9月至2025年6月在医疗技术制造商Augmedics，Inc.担任首席财务官。在此之前，他于2020年9月至2021年8月在医疗科技公司ApiJect Systems Corp.担任首席财务官。在此之前，Asarpota先生于2017年9月至2020年12月担任医疗器械公司NuVasive，Inc.的首席财务官。在此之前，Asarpota先生曾担任放射服务公司Imaging Advantage，LLC的首席财务官、实验室设备和供应制造商Cole Parmer Instrument Company的首席财务官和首席运营官，Questcor Pharmaceuticals, Inc.的首席财务官和首席会计官，以及Life Technologies和通用电气公司的多个高管或高级管理职位。Asarpota先生拥有马凯特大学MBA学位和孟买大学商学学士学位。
Raj Asarpota has served as Maravai Lifesciences Holdings, Inc.'s Chief Financial Officer since June 2025. Prior to joining Maravai, he served as Chief Financial Officer of Augmedics, Inc., a medical technology manufacturer, from September 2021 to June 2025. Prior to that, he served as Chief Financial Officer of ApiJect Systems Corp., a medical technology company, from September 2020 to August 2021. Before that, Mr. Asarpota served as Chief Financial Officer of NuVasive, Inc., a medical device company, from September 2017 to December 2020. Prior to that, Mr. Asarpota served as Chief Financial Officer of Imaging Advantage, LLC, a radiology services company, Chief Financial Officer and Chief Operating Officer of Cole Parmer Instrument Company, a lab equipment and supply manufacturer, and Chief Financial Officer and Principal Accounting Officer of Questcor Pharmaceuticals, Inc., as well as various executive or senior management positions at Life Technologies and General Electric Company. Mr. Asarpota holds an MBA from Marquette University and a Bachelor of Commerce from the University of Mumbai.- Raj Asarpota自2025年6月起担任Maravai Lifesciences Holdings, Inc.的首席财务官。在加入Maravai之前，他于2021年9月至2025年6月在医疗技术制造商Augmedics，Inc.担任首席财务官。在此之前，他于2020年9月至2021年8月在医疗科技公司ApiJect Systems Corp.担任首席财务官。在此之前，Asarpota先生于2017年9月至2020年12月担任医疗器械公司NuVasive，Inc.的首席财务官。在此之前，Asarpota先生曾担任放射服务公司Imaging Advantage，LLC的首席财务官、实验室设备和供应制造商Cole Parmer Instrument Company的首席财务官和首席运营官，Questcor Pharmaceuticals, Inc.的首席财务官和首席会计官，以及Life Technologies和通用电气公司的多个高管或高级管理职位。Asarpota先生拥有马凯特大学MBA学位和孟买大学商学学士学位。
- Raj Asarpota has served as Maravai Lifesciences Holdings, Inc.'s Chief Financial Officer since June 2025. Prior to joining Maravai, he served as Chief Financial Officer of Augmedics, Inc., a medical technology manufacturer, from September 2021 to June 2025. Prior to that, he served as Chief Financial Officer of ApiJect Systems Corp., a medical technology company, from September 2020 to August 2021. Before that, Mr. Asarpota served as Chief Financial Officer of NuVasive, Inc., a medical device company, from September 2017 to December 2020. Prior to that, Mr. Asarpota served as Chief Financial Officer of Imaging Advantage, LLC, a radiology services company, Chief Financial Officer and Chief Operating Officer of Cole Parmer Instrument Company, a lab equipment and supply manufacturer, and Chief Financial Officer and Principal Accounting Officer of Questcor Pharmaceuticals, Inc., as well as various executive or senior management positions at Life Technologies and General Electric Company. Mr. Asarpota holds an MBA from Marquette University and a Bachelor of Commerce from the University of Mumbai.
- Bernd Brust
Bernd Brust，他曾于2010年担任Life Technologies公司的商业运营总裁，以及Life Technologies公司的分子医学总裁。从2006年11月到2008年11月，他曾担任Invitrogen Corporation（于2008年11月与Applied Biosystems公司合并成Life Technologies公司）的负责全球销售的高级副总裁。他于2004年加入Invitrogen Corporation，也曾担任总经理兼欧洲运营副总裁（直到2006年11月）。加入Invitrogen Corporation之前，他曾担任GE Medical Systems Information Technologies公司的多种高级领导职务，包括负责销售和营销的总经理。他持有MTS（位于阿姆斯特丹）的工程学位。他是the San Diego Regional Chamber of Commerce、BIOCOM（世界上最大的地区生命科学协会）的董事会成员，并代表南加州的550多家公司。
Bernd Brust served as President of Commercial Operations of Life Technologies in 2010and is now the President of Molecular Medicine of Life Technologies. From November 2006 to November 2008Mr. Brust served as Senior Vice President of Global Sales of Invitrogen Corporation,which merged with Applied Biosystems in November 2008 to form Life Technologies. Mr. Brust joined Invitrogen Corporation in 2004 and served as General Manager and Vice President of European Operations until November 2006. Prior to joining Invitrogen Corporation,he served in various senior leadership roles at GE Medical Systems Information Technologies,including as General Manager of Sales & Marketing. Mr. Brust holds a degree in Engineering from MTS in Amsterdam. Mr. Brust is a board member of the San Diego Regional Chamber of Commerce and BIOCOM,the largest regional life science association in the world,representing more than 550 member companies in Southern California.- Bernd Brust，他曾于2010年担任Life Technologies公司的商业运营总裁，以及Life Technologies公司的分子医学总裁。从2006年11月到2008年11月，他曾担任Invitrogen Corporation（于2008年11月与Applied Biosystems公司合并成Life Technologies公司）的负责全球销售的高级副总裁。他于2004年加入Invitrogen Corporation，也曾担任总经理兼欧洲运营副总裁（直到2006年11月）。加入Invitrogen Corporation之前，他曾担任GE Medical Systems Information Technologies公司的多种高级领导职务，包括负责销售和营销的总经理。他持有MTS（位于阿姆斯特丹）的工程学位。他是the San Diego Regional Chamber of Commerce、BIOCOM（世界上最大的地区生命科学协会）的董事会成员，并代表南加州的550多家公司。
- Bernd Brust served as President of Commercial Operations of Life Technologies in 2010and is now the President of Molecular Medicine of Life Technologies. From November 2006 to November 2008Mr. Brust served as Senior Vice President of Global Sales of Invitrogen Corporation,which merged with Applied Biosystems in November 2008 to form Life Technologies. Mr. Brust joined Invitrogen Corporation in 2004 and served as General Manager and Vice President of European Operations until November 2006. Prior to joining Invitrogen Corporation,he served in various senior leadership roles at GE Medical Systems Information Technologies,including as General Manager of Sales & Marketing. Mr. Brust holds a degree in Engineering from MTS in Amsterdam. Mr. Brust is a board member of the San Diego Regional Chamber of Commerce and BIOCOM,the largest regional life science association in the world,representing more than 550 member companies in Southern California.